Atorvastatin and Pulmonary Pressure

Phase 2

• Conditions: Condition 1: COPD. Condition 2: Pulmonary hypertension.; Chronic lower respiratory diseases; Pulmonary heart disease, unspecified

• Registration Number: IRCT2013051213299N1
• Lead Sponsor: Vice chancellor for research of Arak University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

Resting pulmonary blood pressure>25mmHg; functional class II, III; ability of take part in 6 min walk test.
Exclusion criteria: Cardiac diseases, Systolic blood pressure>180mmHg, Diastolic blood pressure>100mmHg, Heart rate>120/min; heart failure (LVEF<50%); no compliance, history of allergy to atorvastatin, COPD exacerbation; stroke in recent 3 months.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pulmonary Artery Blood Pressure. Timepoint: before and 3 months after intervention. Method of measurement: Echocardiographic study.;Right ventricle ejection fraction. Timepoint: Before intervention and 3 months later. Method of measurement: TAPSE in Echocardiographic study.;Systolic Blood Pressure. Timepoint: Before and after 6 minute walk test, before and 3 months after intervention. Method of measurement: mmHg, Mercury barometer.;Diastolic Blood Pressure. Timepoint: before and after of 6 minute walk test, before and 3 months after intervention. Method of measurement: mmHg, Mercury barometer.;Heart Rate. Timepoint: before and after 6 minute walk test, before and 3 months after intervention. Method of measurement: Rate/ Minute.;Total distance in 6MWT. Timepoint: before and 3 months after intervention. Method of measurement: Meter.